Celldex Therapeutics, Inc. (CLDX)
$46.25
Rating:
Recommendation:
Neutral
| Symbol | CLDX |
|---|---|
| Price | $46.25 |
| Beta | 2.278 |
| Volume Avg. | 0.49M |
| Market Cap | 2.178B |
| Shares () | - |
| 52 Week Range | 19.85-48.4 |
| 1y Target Est | - |
| DCF Unlevered | CLDX DCF -> | |
|---|---|---|
| DCF Levered | CLDX LDCF -> | |
| ROE | -27.74% | Sell |
| ROA | -28.70% | Sell |
| Operating Margin | - | |
| Debt / Equity | 6.89% | Neutral |
| P/E | - | |
| P/B | 6.28 | Strong Buy |
Latest CLDX news
About
Download (Excel)Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.